Loading clinical trials...

TERMINATEDNA

POWER UP: Participating Online While Exercising to Recover Using Play

NCT05308407•M.D. Anderson Cancer Center

Summary

We will conduct a two-phase study. The first phase is to adapt and develop an active video game (AVG)-centered lifestyle physical activity (PA) intervention (POWER UP) for adolescents and young adults (AYA) with central nervous system tumors. The second phase is to test the feasibility and preliminary efficacy of a 12-week virtually delivered, group-based active video game-centered lifestyle physical activity intervention on function and quality of life in AYAs (aged 15-39) who are ≤1-year post-surgery for a central nervous system tumor. This population is at very high-risk for steep functional decline.

Detailed Description

Objective: To develop (Aim 1) and test (Aim2, Primary Objective) the feasibility and acceptability of a virtually delivered, group-based active video game-centered lifestyle physical activity intervention targeting affect to improve function and quality of life in insufficiently active AYAs with central nervous system tumors. Also, (Aim 2, Secondary Objective) in a pilot randomized trial, compare the physical function, quality of live, and physical activity level between intervention and control groups. Primary: Feasibility and acceptability of the POWER UP intervention and assessments. Secondary: Physical function, quality of life (QOL), symptoms, and PA levels as measured at the 12- and 24-week follow ups . Other endpoints relevant to the primary and secondary objectives: BMI status, dietary intake, Fitbit data (days worn and steps), exercise motivation, basic psychological needs at the 12- and 24-week follow-ups

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•In order to be eligible to participate in Aim 1 of this study, an individual must meet all of the following criteria:
•Round 1 focus groups:
•1. Oncologists who are caring for AYA cancer survivors or
•2. Survivorship care providers who actively engage with AYA cancer survivors
•Round 2 focus groups:
•1. AYA cancer survivors age 15-39 years old
•2. Self-reported diagnosis of a primary benign or malignant CNS tumor or confirmed diagnosis of primary benign or malignant CNS tumor radiographically or pathologically when available
•3. ≤1-year post surgery and can have other tumor-directed treatment (e.g., radiation and/or chemotherapy)
•4. Participants and/or guardians are willing and able to provide informed consent
•5. Able to speak, read, and understand English
+15 more criteria

Exclusion Criteria

•An individual who meets any of the following criteria will be excluded from participation in Aim 1 of this study:
•Round 1 Focus Groups:
•1\. Do not have access to the internet
•Round 2 Focus Groups:
•1. Another member of the household is a participant or staff member on this trial
•2. Do not have access to the internet
•3. In foster care or is incarcerated
•4. Cognitive and/or major sensory deficits that would impede the completion of research activities and assessments as deemed by the clinical team.
•5. Self-reported diagnosis of a metastatic CNS tumor or confirmed diagnosis of a metastatic CNS tumor radiographically or pathologically when available
•An individual who meets any of the following criteria will be excluded from participation in Aim 2 of this study:
+8 more criteria

Locations (1)

M D Anderson Cancer Center

Houston, Texas, United States

Key Dates

Start Date

May 4, 2022

Primary Completion Date

July 29, 2025

Completion Date

July 29, 2025

Last Updated

August 5, 2025

Enrollment

ACTUAL participants

Conditions

ExerciseCentral Nervous System TumorsTumors

Interventions

Focus Groups

OTHER

Pilot randomized controlled trial

OTHER

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

NCT06898450

Advanced Solid Tumors CancerMSI-H Cancer

View study

RECRUITING

DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

NCT01247597

Pleuropulmonary BlastomaCystic Nephroma+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 5, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

POWER UP: Participating Online While Exercising to Recover Using Play

Inclusion Criteria

Exclusion Criteria

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

Sustaining Physical Activity After Cancer Exercise Sessions

Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

A Study of ASP1002 in Adults for Treatment of Solid Tumors

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors